Format

Send to

Choose Destination
Mol Med Today. 2000 Oct;6(10):398-402.

RAS inhibitors: potential for cancer therapeutics.

Author information

1
Department of Neurobiochemistry, The George S. Wise Faculty of Life Sciences, Tel-Aviv University, 69978, Tel-Aviv, Israel. kloog@post.tau.ac.il

Abstract

As RAS oncoproteins play a major role in human malignancy, inhibiting RAS function is a promising approach for developing anticancer therapies. Among these approaches are agents such as farnesyltransferase inhibitors (FTIs) and the nontoxic farnesylcysteine analogue farnesylthiosalicylic acid (FTS) that dislodges all RAS isoforms from the membrane, as well as methods to restore regulation of RAS-GTP levels and to alter the interaction of RAS-GTP with downstream targets.

PMID:
11006529
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center